Rheumatoid arthritis treatment is often complex. If patients do not respond to therapy, the question arises as to which drugs can help.
62-year-old woman with fatigue, jaundice, fever, and kidney injury. Can you guess the diagnosis?
No available medical therapy has resulted in a reduction in mortality among patients with HFpEF. Therefore, the current aims of medical treatment are to reduce the risk of hospitalization and improve quality of life.
Dr. James Styner transformed trauma care after a 1976 plane crash, creating the ATLS protocol (now a global benchmark) to standardize emergency treatment.
Current guidelines recommend routine postoperative hormone treatment to control pain in endometriosis. But which treatment regimen is most effective?
A study shows that as a result of the “close parent intervention” program, FCC practices were improved in 8 NICUs.
A recent cost-effectiveness analysis addressed the question of the appropriate age for the start and end of screening colonoscopies.
Liver transplantation is a rapidly developing field. Advanced technologies, like AI, will improve access, outcomes, and offer more personalized care.
Tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with relapsed or refractory follicular lymphoma.
Auto-SCT did not improve mantle cell lymphoma with undetectable minimal residual disease outcomes after induction therapy.
Daratumumab plus lenalidomide had superior PFS outcomes vis-a-vis lenalidomide plus dexamethasone in frail patients with untreated MM.
Allo-SCT was more efficacious than standard-of-care in paediatric patients with sickle cell anaemia and abnormal cerebral artery velocities.
For VTE patients who needed extended anticoagulation, a reduced DOAC dose did not meet non-inferiority criteria for efficacy, compared to full DOACs.
Three novel mezigdomide-based triplet therapies seem tolerated and associated with anti-tumour activity in patients with relapsed or refractory MM.
Axicabtagene ciloleucel was associated with durable responses and long-term survival in relapsed or refractory indolent non-Hodgkin lymphoma.
Uproleselan + chemotherapy did not outperform chemotherapy alone for relapsed or refractory AML; but authors saw interesting trends in subgroups.
A man in his 60s enters the ER after two fainting spells on the same day. The previous night he was woken up by severe palpitations. How to proceed?
Daratumumab reduced progression to multiple myeloma and prolonged overall survival in patients with high-risk smouldering MM.
The investigational therapy GLPG5101 was associated with high response and a favourable safety profile in relapsed or refractory non-Hodgkin lymphoma.
Rilzabrutinib improved efficacy and QoL outcomes over placebo with a favourable safety profile among heavily pre-treated adults with immune thrombocytopenia.